

JAMA | Original Investigation

# Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With *E coli* or *Klebsiella pneumoniae* Bloodstream Infection and Ceftriaxone Resistance

## A Randomized Clinical Trial

Patrick N. A. Harris, MBBS; Paul A. Tambyah, MD; David C. Lye, MBBS; Yin Mo, MBBS; Tau H. Lee, MBBS; Mesut Yilmaz, MD; Thamer H. Alenazi, MD; Yaseen Arabi, MD; Marco Falcone, MD; Matteo Bassetti, MD, PhD; Elda Righi, MD, PhD; Benjamin A. Rogers, MBBS, PhD; Souha Kanj, MD; Hasan Bhally, MBBS; Jon Iredell, MBBS, PhD; Marc Mendelson, MBBS, PhD; Tom H. Boyles, MD; David Looke, MBBS; Spiros Miyakis, MD, PhD; Genevieve Walls, MB, ChB; Mohammed Al Khamis, MD; Ahmed Zikri, PharmD; Amy Crowe, MBBS; Paul Ingram, MBBS; Nick Daneman, MD; Paul Griffin, MBBS; Eugene Athan, MBBS, MPH, PhD; Penelope Lorenc, RN; Peter Baker, PhD; Leah Roberts, BSc; Scott A. Beatson, PhD; Anton Y. Peleg, MBBS, PhD; Tiffany Harris-Brown, RN, MPH; David L. Paterson, MBBS, PhD; for the MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN)

**IMPORTANCE** Extended-spectrum  $\beta$ -lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in *Escherichia coli* and *Klebsiella pneumoniae*. Significant infections caused by these strains are usually treated with carbapenems, potentially selecting for carbapenem resistance. Piperacillin-tazobactam may be an effective "carbapenem-sparing" option to treat extended-spectrum  $\beta$ -lactamase producers.

**OBJECTIVES** To determine whether definitive therapy with piperacillin-tazobactam is noninferior to meropenem (a carbapenem) in patients with bloodstream infection caused by ceftriaxone-nonsusceptible *E coli* or *K pneumoniae*.

**DESIGN, SETTING, AND PARTICIPANTS** Noninferiority, parallel group, randomized clinical trial included hospitalized patients enrolled from 26 sites in 9 countries from February 2014 to July 2017. Adult patients were eligible if they had at least 1 positive blood culture with *E coli* or *Klebsiella* spp testing nonsusceptible to ceftriaxone but susceptible to piperacillin-tazobactam. Of 1646 patients screened, 391 were included in the study.

**INTERVENTIONS** Patients were randomly assigned 1:1 to intravenous piperacillin-tazobactam, 4.5 g, every 6 hours (n = 188 participants) or meropenem, 1 g, every 8 hours (n = 191 participants) for a minimum of 4 days, up to a maximum of 14 days, with the total duration determined by the treating clinician.

**MAIN OUTCOMES AND MEASURES** The primary outcome was all-cause mortality at 30 days after randomization. A noninferiority margin of 5% was used.

**RESULTS** Among 379 patients (mean age, 66.5 years; 47.8% women) who were randomized appropriately, received at least 1 dose of study drug, and were included in the primary analysis population, 378 (99.7%) completed the trial and were assessed for the primary outcome. A total of 23 of 187 patients (12.3%) randomized to piperacillin-tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6% [1-sided 97.5% CI,  $-\infty$  to 14.5%];  $P = .90$  for noninferiority). Effects were consistent in an analysis of the per-protocol population. Nonfatal serious adverse events occurred in 5 of 188 patients (2.7%) in the piperacillin-tazobactam group and 3 of 191 (1.6%) in the meropenem group.

**CONCLUSIONS AND RELEVANCE** Among patients with *E coli* or *K pneumoniae* bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in a noninferior 30-day mortality. These findings do not support use of piperacillin-tazobactam in this setting.

**TRIAL REGISTRATION** anzctr.org.au Identifiers: [ACTRN12613000532707](https://anzctr.org.au/identifiers/ACTRN12613000532707) and [ACTRN12615000403538](https://anzctr.org.au/identifiers/ACTRN12615000403538) and ClinicalTrials.gov Identifier: [NCT02176122](https://clinicaltrials.gov/identifiers/NCT02176122)

JAMA. 2018;320(10):984-994. doi:10.1001/jama.2018.12163

← Editorial page 979

+ Video and Supplemental content

+ CME Quiz at [jamanetwork.com/learning](http://jamanetwork.com/learning) and CME Questions page 1033

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Group Information:** MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) are listed at the end of this article.

**Corresponding Author:** David L. Paterson, MBBS, PhD, University of Queensland Centre for Clinical Research, Faculty of Medicine, Bldg 71/918 Royal Brisbane & Women's Hospital Campus, Herston, QLD 4029, Australia ([d.paterson1@uq.edu.au](mailto:d.paterson1@uq.edu.au)).

Gram-negative bacteria that produce extended-spectrum  $\beta$ -lactamase (ESBL) enzymes are a global public health concern.<sup>1</sup> Based on national surveillance data from 2011, the US Centers for Disease Control and Prevention estimated that ESBL producers accounted for at least 26 000 infections and 1700 deaths annually.<sup>2</sup> A key feature of ESBL-producing *Enterobacteriaceae* is phenotypic resistance to oxyiminocephalosporins, in addition to penicillins.<sup>3</sup> ESBL producers are increasingly commonplace in both community and health care settings.<sup>4</sup> Carbapenems have been regarded as the treatment of choice for serious infections caused by ESBL producers.<sup>3,5</sup> However, increased use of carbapenems may select for carbapenem resistance in gram-negative bacilli,<sup>6,7</sup> which currently represents the greatest threat in terms of antibiotic resistance.

One strategy to reduce the global use of carbapenems could be to reevaluate alternative agents (ie, carbapenem-sparing regimens).  $\beta$ -Lactam/ $\beta$ -lactamase inhibitor (BLBLI) combination antibiotics, such as piperacillin-tazobactam, have been considered a carbapenem-sparing option for treatment of ESBL producers.<sup>8,9</sup> ESBL enzymes are inhibited by tazobactam, and ESBL producers are frequently susceptible to BLBLIs in vitro.

Some observational studies have suggested that BLBLIs may be clinically effective for treating infections caused by ESBL producers,<sup>10-13</sup> but conflicting results have been reported.<sup>14</sup> This study aimed to test the hypothesis that a carbapenem-sparing regimen (piperacillin-tazobactam) is noninferior to a carbapenem (meropenem) for the definitive treatment of bloodstream infection (BSI) caused by ceftriaxone-nonsusceptible *Escherichia coli* or *Klebsiella* spp that test susceptible to piperacillin-tazobactam.

## Methods

### Study Design and Inclusion Criteria

The trial protocol was developed by the Australasian Society for Infectious Disease Clinical Research Network and has been previously published.<sup>15</sup> The full protocol is provided in Supplement 1. The protocol was designed to be pragmatic and reflect usual clinical care (PRECIS-2 diagram<sup>16</sup>; eFigure 7 in Supplement 2). The institutional review board for each recruiting center approved the protocol. Written informed consent was obtained from all patients or their appropriate representative. The results are reported in accordance with the CONSORT statement extension for Non-inferiority and Equivalence Trials.<sup>17</sup>

This was an international, multicenter, open-label, parallel group, randomized clinical trial of piperacillin-tazobactam vs meropenem for the definitive treatment of BSI caused by ceftriaxone-nonsusceptible *E coli* or *Klebsiella* spp. Adult patients (aged  $\geq 18$  years or  $\geq 21$  years in Singapore) were eligible for enrollment if they had at least 1 positive blood culture with *E coli* or *Klebsiella* spp that was nonsusceptible to ceftriaxone or cefotaxime, but remained susceptible to piperacillin-tazobactam and meropenem according to local laboratory protocols. Patients had to be randomized within 72 hours of initial positive blood culture collection. Exclusion criteria included

## Key Points

**Question** Can piperacillin-tazobactam be used as carbapenem-sparing therapy in patients with bloodstream infections caused by ceftriaxone-resistant *Escherichia coli* or *Klebsiella pneumoniae*?

**Findings** In this noninferiority randomized clinical trial that included 391 patients with *E coli* or *K pneumoniae* bloodstream infection and ceftriaxone resistance, the 30-day mortality rate for patients treated with piperacillin-tazobactam compared with meropenem was 12.3% vs 3.7%, respectively. The difference did not meet the noninferiority margin of 5%.

**Meaning** These findings do not support piperacillin-tazobactam compared with meropenem for these infections.

allergy to either trial drug or similar antibiotic classes, no expectation of survival more than 96 hours, treatment without curative intent, polymicrobial bacteremia (likely skin contaminants excepted), previous enrollment in the trial, pregnancy or breastfeeding, or requirement for concomitant antibiotics with activity against gram-negative bacilli. The primary treating clinician also had to agree to enrollment in the study prior to randomization.

### Study Population, Stratification, and Randomization

Patients were screened for enrollment in 26 hospitals in 9 countries (Australia, New Zealand, Singapore, Italy, Turkey, Lebanon, South Africa, Saudi Arabia, and Canada) from February 2014 to July 2017 (eFigure 3 in Supplement 2). Patients were stratified according to infecting species (*E coli* or *Klebsiella* spp; groups E or K), presumed source of infection (urinary tract or elsewhere), and severity of disease (Pitt bacteremia score  $\leq 4$  or  $> 4$ ). A high-risk stratum (E2 or K2) was defined by nonurinary source for BSI and Pitt score greater than 4 (eFigure 1 in Supplement 2).

Patients were randomly assigned to either meropenem or piperacillin-tazobactam in a 1:1 ratio according to a randomization list prepared in advance for each recruiting site and stratification. The sequence was generated using random permuted blocks of 2 and 4 patients, with the allocated drug revealed using an online randomization module within the REDCap data management system.<sup>18</sup> All records were verified using double-data entry, with reference to the paper clinical record form.

### Intervention and Follow-up

Meropenem, 1 g, was administered every 8 hours intravenously. Piperacillin-tazobactam, 4.5 g, was administered every 6 hours intravenously. Each dose of study drug was infused over 30 minutes. Study drug was administered for a minimum of 4 calendar days after randomization and up to 14 days, with the total duration of therapy determined by the treating clinician. Dose adjustment for renal impairment was made according to criteria specified in the trial protocol. The treating clinicians and investigators were not blinded to the treatment allocation.

All patients had a blood culture collected at day 3 after randomization or on any other day if febrile (temperature  $>38^{\circ}\text{C}$ ) up to day 5. Patients were followed up for 30 days after randomization, by telephone call if the patient was discharged from hospital. All patients had baseline clinical and demographic data recorded, as well as any antibiotics given up to 48 hours prior to initial positive blood culture and for 30 days after randomization. Clinical data were recorded daily from day of initial positive blood culture until day 5 after randomization (with day 1 being the day of randomization, which had to occur within 72 hours of initial blood culture collection) (eTable 1 in Supplement 2). On day 5, the primary treating team had the option to cease all antibiotics, continue the allocated agent or change to step-down therapy (eFigure 2 in Supplement 2).

### Definitions

Empirical therapy was defined as antibiotic therapy given in the period prior to enrollment following the collection of the initial positive blood culture. Empirical therapy was defined as “appropriate” if commenced within 24 hours of initial blood culture collection and the blood isolate was susceptible in vitro to the chosen agent(s). Study drug represented definitive therapy, ie, therapy given when results of susceptibility testing were known. Treatment duration included the days of commencement and cessation of the drug.

### Outcomes

The primary efficacy outcome was all-cause mortality at 30 days after randomization. Secondary outcomes included (1) time to clinical and microbiologic resolution of infection, defined as the number of days from randomization to resolution of fever (temperature  $>38.0^{\circ}\text{C}$ ) and leukocytosis (white blood cell count  $>12\,000/\mu\text{L}$ ; to convert to  $\times 10^9/\text{L}$ , multiply by 0.001) plus sterilization of blood cultures; (2) clinical and microbiologic success at day 4 after randomization, defined as survival plus resolution of fever and leukocytosis plus sterilization of blood cultures; (3) microbiologic resolution of infection, defined as sterility of blood cultures collected on or before day 4 after randomization; (4) relapsed bloodstream infection, defined as growth of the same organism as in the original blood culture after the end of the period of study drug administration but before day 30 after randomization; and (5) secondary infection with a meropenem- or piperacillin-tazobactam-resistant organism or *Clostridium difficile* infection, defined as growth of a meropenem- or piperacillin-tazobactam-resistant gram-negative organism from any clinical specimen collected from day 4 after randomization to day 30 or a positive *C difficile* stool test in the setting of diarrhea. Adverse events were documented for each study group. Other BSI events (caused by organisms other than *E coli* or *Klebsiella* spp) were also recorded up to 30 days. For any missing repeated variable used to define clinical resolution (eg, daily white blood cell count), the last observation was carried forward until a new observation was recorded.

### Microbiological Studies

Bacteria isolated from blood cultures in enrolled patients were available for further analysis at the coordinating lab-

oratory. Minimum inhibitory concentrations (MICs) for piperacillin-tazobactam and meropenem were determined by MIC test strips (bioMérieux and Liofilchem) and interpreted according to standards defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST).<sup>19</sup> ESBL production was confirmed by combination disc testing with clavulanate.<sup>20</sup> Whole-genome sequencing was performed as previously described<sup>21</sup> (eTables 8-10 and eFigure 6 in the “Whole-Genome Sequencing Methods” section of Supplement 2) to determine sequence types (STs) and characterize  $\beta$ -lactamase genes.

### Sample Size Calculation

Because no randomized clinical trials have previously compared treatment options for ESBL producers causing BSI, the sample size estimation was derived from the largest retrospective study available at the time.<sup>10</sup> The overall 30-day mortality in this observational study was 16.7% in those receiving a carbapenem. Based on a mortality rate of 14% in the control group (assuming mortality in observational cohorts may be greater than in trials with exclusion criteria) and a noninferiority margin of 5%, 454 patients were needed in total to achieve 80% power with a 1-sided  $\alpha$  level of .025, allowing for 10% dropout.<sup>22</sup> A 5% noninferiority margin was chosen as the maximal difference in mortality between treatments that would be clinically acceptable, by consultation with infectious disease, critical care, and clinical trial specialists of the Australasian Society for Infectious Disease Clinical Research Network involved in the protocol development.<sup>15</sup>

### Statistical Analysis

The primary analysis population was defined as any correctly randomized patient receiving at least 1 dose of allocated drug and was used to make inference on noninferiority of the treatment group (piperacillin-tazobactam), compared with control (meropenem), in terms of the primary outcome (30-day mortality). This was supported by an analysis of the per-protocol (PP) population. Protocol deviations defining exclusion from the primary analysis and inclusion in the PP sample were adjudicated by an assessor blinded to treatment allocation. The proportions of deaths in the study groups were calculated, with absolute risk differences determined with the meropenem group as the reference. The Miettinen-Nurminen method (MNM) was used to determine 1-sided 97.5% CIs for risk differences.<sup>23</sup> As a multisite study, alternate methods were also examined including scorebased methods, which extend MNM<sup>24</sup> and logistic regression with sites as fixed and random effects. Because the risk differences and confidence intervals for the primary and secondary outcomes were similar when estimated by MNM or logistic regression, results for the MNM are presented. Noninferiority of all-cause mortality at 30 days would be established if the upper bound of the 1-sided 97.5% CI did not cross the margin of 5%.

For secondary outcomes, parametric and nonparametric tests were used as appropriate, depending on whether the data were normally distributed. Because the secondary outcomes were considered exploratory, adjustments for multiple

comparisons were not made. For secondary outcomes, statistical tests were 2-sided, with a  $P < .05$  considered significant. An analysis of the primary end point was undertaken in prespecified subgroups: (1) urinary vs nonurinary source, (2) Pitt bacteremia score of 4 or greater or less than 4, (3) *E coli* vs *K pneumoniae*, (4) appropriate vs inappropriate empirical therapy, and (5) health care-associated vs non-health care-associated BSI. In addition, a post hoc analysis was undertaken of high-income vs middle-income countries (using Organization for Economic Cooperation and Development Development Assistance Committee definitions, <http://www.oecd.org/dac>) and patients with the presence or absence of immune compromise.

The homogeneity of treatment effects on the primary outcome was explored across subgroups using a test for the intervention by subgroup interaction by adding this term and the subgroup as covariates in a logistic regression model, using a 2-sided significance level of  $P < .05$ . To quantify the effect of missing data on secondary outcomes, a post hoc sensitivity analysis using multiple imputation was performed using multivariate imputation by chained equations for both discrete and continuous data,<sup>25</sup> with computation via the ‘mice’ package in R version 3.5.0.<sup>26</sup>

Baseline patient characteristics were tabulated, with proportions for categorical variables, mean and SDs for normally distributed continuous variables, or median and interquartile ranges for skewed data. The influence of clinical variables other than randomized antibiotic therapy on the primary outcome was also explored in a multivariable logistic regression model, including the treatment group as an independent variable. Any variables associated with the primary outcome on bivariable analysis (2-sided  $P < .20$ ) were included in a multivariable logistic regression model (ie, urinary tract source, Pitt score, Charlson Comorbidity Index score, Organization for Economic Cooperation and Development region, immune compromise, and health care-associated infection). The model was optimized using a step-wise approach, beginning with the bivariable model most strongly associated with the primary outcome. The goodness-of-fit of the model after each step was assessed using Akaike’s information criteria. Variables that did not improve the model fit were excluded. Adjusted odds ratios for the effect of the intervention on the primary outcome with 1-sided 97.5% CIs were calculated. Analysis of raw data to determine primary and secondary outcomes, including missing value imputation via last value carried forward where appropriate, was performed in R version 4.3.1,<sup>27</sup> with subsequent statistical testing undertaken using Stata version 15.1 (StataCorp). The full statistical analysis plan is provided in Supplement 1.

### Study Monitoring

A data and safety monitoring board (DSMB) was established, comprising 2 independent infectious disease physicians with support provided by an independent statistician. Interim analyses were performed after the first 50, 150, and 340 patients completed the 30-day follow-up period. The predefined stopping rule for superiority was a statistically significant difference (at a significance level of  $P < .001$ ) in primary outcome.

## Results

### Demographic and Clinical Characteristics of Patients

A total of 1646 patients were screened during the trial period. Of these, 391 (23.8%) were randomized, although 12 patients (8 in the piperacillin-tazobactam group and 4 in the meropenem group) were randomized in error or did not receive the allocated study drug and were therefore excluded from the primary analysis population, which included 379 patients at baseline (191 received meropenem and 188 received piperacillin-tazobactam) (Figure 1). One patient who received piperacillin-tazobactam self-discharged against medical advice and was lost to follow-up, so the total number of patients who were evaluated for the primary outcome was 378. Baseline demographic and clinical details are summarized in Table 1. Overall, treatment groups were balanced with respect to baseline characteristics, although more patients in the meropenem group had diabetes (41.4% vs 31.4%), a urinary tract source for BSI (67.0% vs 54.8%), and higher APACHE II scores (21.0 vs 17.9). More patients in the piperacillin-tazobactam group had immune compromise (27.1% vs 20.9%) but had a shorter time to receipt of microbiologically appropriate antibiotics from onset of infection (5.5 hours vs 9.6 hours). By the day of randomization, 40.7% patients had resolved objective markers of infection (as defined in the secondary outcome measure of clinical and microbiological resolution), although this was similar between groups (40.3% in the meropenem group and 41.2% in the piperacillin-tazobactam group).


Following the DSMB review at 340 patients enrolled, a difference in the primary outcome was observed, at a significance level approximating the prespecified stopping rule ( $P = .004$ ). As such, the DSMB recommended temporary suspension of the study on July 8, 2017, pending analysis once all 391 randomized patients had completed 30-day follow-up. This analysis showed that completing full enrollment was highly unlikely to demonstrate noninferiority of piperacillin-tazobactam. If the mortality rate observed in the piperacillin-tazobactam group at the interim analysis were to remain unchanged, it would have required a mortality rate greater than 43% in the meropenem group to conclude noninferiority at the 5% threshold. Even if mortality dropped to 6% in the piperacillin-tazobactam group, mortality greater than 34% in the meropenem group would be necessary. A decision to terminate the study on the grounds of harm and futility was made by the study management team, after discussion with site investigators, on August 10, 2017. This decision was made independently from the DSMB.

### Primary Outcome

A total of 23 of 187 patients (12.3%) within the primary analysis population randomized to receive piperacillin-tazobactam as definitive therapy met the primary outcome of all-cause mortality at 30 days compared with 7 of 191 (3.7%) in the meropenem group (risk difference, 8.6% [1-sided 97.5% CI,  $-\infty$  to 14.5%];  $P = .90$  for noninferiority) (eFigure 4 in Supplement 2). Results were consistent within the PP population, with 18 of 170 patients (10.6%) meeting the primary



Figure 1. Patient Recruitment, Randomization, and Flow Through Study



outcome in the piperacillin-tazobactam group compared with 7 of 186 (3.8%) in the meropenem group (risk difference, 6.8% [one-sided 97.5% CI,  $-\infty$  to 12.8%];  $P = .76$  for noninferiority) (Table 2). Adjustment for a urinary tract source of infection and the Charlson Comorbidity Index score resulted in little change in the findings (unadjusted odds ratio, 3.69 [1-sided 97.5% CI, 0 to 8.82]; adjusted odds ratio, 3.41 [1-sided 97.5% CI, 0 to 8.38]) (eTable 5 in Supplement 2).

**Secondary Outcomes**

Clinical and microbiological resolution by day 4 occurred in 121 of 177 patients (68.4%) in the piperacillin-tazobactam group compared with 138 of 185 (74.6%), randomized to meropenem (risk difference,  $-6.2\%$  [95% CI,  $-15.5$  to  $3.1\%$ ];  $P = .19$ ) (Figure 2). The median day of resolution of signs of infection after randomization was 3 (interquartile range [IQR], 1,5) in the piperacillin-tazobactam group, and 2 (IQR, 1,5) in the meropenem group, but this difference was not significant ( $P = .18$ ) (eFigure 5 in Supplement 2). There were also no significant differences in microbiological resolution by day 4 or rates of microbiological relapse, secondary infection with another multiresistant organism, or *C difficile* (Figure 2). Patients receiving

piperacillin-tazobactam did not have significantly lower rates of subsequent detection of carbapenem-resistant organisms, although this event was infrequent (3.2% vs 2.1%) (Figure 2). The secondary outcomes were also consistent within the PP population. In subgroup analyses of the primary outcome within the primary analysis population, none of the tests for interaction were significant and none of the subgroups met the noninferiority margin. In addition, the direction of risk associated with randomization to piperacillin-tazobactam remained in favor of meropenem across all subgroups (Table 2). Multiple imputation analysis for missing values showed no differences in results for the analysis of secondary outcomes when compared with the last observation carried forward method (Missing Value Method Comparisons section and eTable 11 in Supplement 2).

**Adverse Events**

Nonfatal serious adverse events occurred in 5 of 188 patients (2.7%) in the piperacillin-tazobactam group compared with 3 of 191 (1.6%) in the meropenem group. Details of all deaths and serious adverse events can be found in eTables 6 and 7 in Supplement 2.

Table 1. Baseline Characteristics of Patients in the Primary Analysis Population<sup>a</sup>

Characteristic	Pipercillin-Tazobactam (n = 188)	Meropenem (n = 191)
Organism		
<i>Escherichia coli</i>	162 (86.2)	166 (86.9)
<i>Klebsiella pneumoniae</i>	26 (13.8)	25 (13.1)
Stratification <sup>b</sup>		
E1 ( <i>E coli</i> , less severe infection)	159 (84.6)	162 (84.8)
E2 ( <i>E coli</i> , more severe infection)	3 (1.6)	3 (1.6)
K1 ( <i>K pneumoniae</i> , less severe infection)	23 (12.2)	25 (13.1)
K2 ( <i>K pneumoniae</i> , more severe infection)	3 (1.6)	1 (0.5)
Country		
Singapore	72 (38.3)	82 (42.9)
Australia	42 (22.3)	43 (22.5)
New Zealand	10 (5.3)	9 (4.7)
Canada	1 (0.5)	1 (0.5)
South Africa	5 (2.7)	6 (3.1)
Italy	15 (8.0)	10 (5.2)
Turkey	24 (12.8)	22 (11.5)
Lebanon	8 (4.3)	7 (3.7)
Saudi Arabia	11 (5.9)	11 (5.8)
Age, median (IQR), y	70 (55-78)	69 (59-78)
Male	101 (53.7)	97 (50.8)
Acquisition		
Hospital-acquired	52 (27.7)	46 (24.1)
Health care-associated	55 (29.3)	61 (31.9)
Community-associated	81 (43.1)	84 (44.0)
Source of bacteremia		
Urinary tract	103 (54.8)	128 (67.0)
Intra-abdominal infection	34 (18.1)	28 (14.7)
Vascular catheter-related infection	3 (1.6)	3 (1.6)
Surgical site infection	8 (4.3)	4 (2.1)
Pneumonia	9 (4.8)	3 (1.6)
Mucositis/neutropenia	12 (6.4)	7 (3.7)
Musculoskeletal	1 (0.5)	0 (0)
Skin and soft tissue	4 (2.1)	1 (0.5)
Other	2 (1.1)	1 (0.5)
Unknown	12 (6.4)	16 (8.4)
Surgery within past 14 d	19 (10.1)	14 (7.3)
ICU admission	13 (7.0)	14 (7.5)
APACHE II Score, mean (SD) <sup>c</sup>	17.9 (6.1)	21.0 (6.9)
Charlson Comorbidity Index score, median (IQR) <sup>d</sup>	2.0 (1.0-4.0)	2.0 (1.0-4.0)
Pitt score, median (IQR) <sup>e</sup>	1.0 (0-2.0)	1.0 (0-2.0)
Immune compromise	51 (27.1)	40 (20.9)
Neutropenia	16 (8.5)	9 (4.7)
Central venous catheter	35 (18.6)	20 (10.5)
Urinary catheter/nephrostomy	51 (27.1)	37 (19.4)
Moderate-severe renal dysfunction <sup>f</sup>	31 (16.5)	30 (15.7)
Diabetes <sup>f</sup>	59 (31.4)	79 (41.4)

(continued)

Table 1. Baseline Characteristics of Patients in the Primary Analysis Population<sup>a</sup> (continued)

Characteristic	Pipercillin-Tazobactam (n = 188)	Meropenem (n = 191)
Liver disease <sup>f</sup>	12 (6.4)	18 (9.4)
qSOFA score $\geq 2$ <sup>g</sup>	86 (45.7)	77 (40.3)
Weight, mean (SD), kg	67.2 (18.1)	69.3 (19.3)
Empirical antibiotic category		
$\beta$ -lactam/ $\beta$ -lactamase inhibitor	38 (20.2)	49 (25.7)
Carbapenem	26 (13.8)	28 (14.7)
Other	124 (66.0)	114 (59.7)
Appropriate empirical antibiotic	126 (67.0)	127 (66.5)
Time to randomization, median (IQR), h	53.6 (44.9-65.6)	52.5 (46.0-63.7)
Time to appropriate antibiotics, median (IQR), h	5.5 (0.4-31.5)	9.6 (0.5-32.1)

Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation score (only collected in ICU-admitted patients); ICU, intensive care unit; IQR, interquartile range; qSOFA, quick sequential organ failure assessment score.

<sup>a</sup> Data are expressed as No. (%) of participants unless otherwise indicated.

<sup>b</sup> Stratum designated by infecting species (*E coli* = E, *K pneumoniae* = K) and disease severity (non-urinary tract source and Pitt score  $>4$  designated as stratum 2, otherwise stratum was 1).

<sup>c</sup> Provides an estimate of ICU mortality, with a score ranging from 0 to 71 (scoring 20-24 signifies a mortality risk of approximately 40%)<sup>28</sup>

<sup>d</sup> Provides a 10-year mortality risk, based on weighted comorbid conditions, ranging from 0 to 29, with a score of 4 associated with an estimated 10-year survival of 53%.<sup>29</sup>

<sup>e</sup> Provides a measure of in-hospital mortality risk in patients with bloodstream infections based on clinical variables, ranging from 0 to 14, with a Pitt score  $\geq 4$  associated with a risk of mortality of approximately 40%.<sup>30</sup>

<sup>f</sup> These variables were determined at the time of enrollment based on the definitions within the Charlson Comorbidity Index score assessment following clinical review by the site investigator.

<sup>g</sup> qSOFA score is a 4-point scale (0-4) used to predict risk in patients with sepsis; a score  $\geq 2$  is associated with a 3- to 14-fold increase in mortality.<sup>31</sup>

## Microbiology

A total of 306 isolates cultured from the blood of patients in the primary analysis population (80.7%) were available for microbiological analysis (n = 266 *E coli* and n = 40 *K pneumoniae*). The median piperacillin-tazobactam MIC was 2 mg/L (IQR, 1.5 mg/L to 4 mg/L). Twelve isolates (3.9%) tested non-susceptible to piperacillin-tazobactam according to the EUCAST breakpoint for susceptibility ( $\leq 8$  mg/L), although only 4 (1.3%) were nonsusceptible if the Clinical and Laboratory Standards Institute breakpoint ( $\leq 16$  mg/L) was applied<sup>32</sup> (eFigure 6 in Supplement 2). There was no significant difference in the median MICs of piperacillin-tazobactam between the treatment groups ( $P = .64$ ), although the median MIC was significantly greater in *K pneumoniae* than *E coli* (4 mg/L vs 2 mg/L;  $P < .001$ ). Most isolates (99.7%) tested susceptible to meropenem (median MIC, 0.023 mg/L; IQR, 0.016 mg/L

Table 2. Primary Analysis and Subgroup Analyses

	30-d Mortality, No./Total No. (%)		Risk Difference, % (1-Sided 97.5% CI) <sup>a</sup>	P Value for Noninferiority
	Piperacillin-Tazobactam	Meropenem		
Primary analysis	23/187 (12.3)	7/191 (3.7)	8.6 (−∞ to 14.5)	.90
Per-protocol analysis	18/170 (10.6)	7/186 (3.8)	6.8 (−∞ to 12.8)	.76
Subgroup analyses <sup>b</sup>				P Value for Interaction
OECD country income				
Middle income	8/37 (21.6)	1/35 (2.9)	18.8 (−∞ to 35.0)	.31
High income	15/150 (10.0)	6/156 (3.9)	6.2 (−∞ to 12.5)	
Pitt score				
≥4	5/18 (27.8)	0/9	27.8 (−∞ to 51.3)	.99
<4	18/169 (10.7)	7/182 (3.9)	6.8 (−∞ to 12.8)	
Infecting species				
<i>E coli</i>	17/161 (10.6)	7/166 (4.2)	6.3 (−∞ to 12.6)	.99
<i>K pneumoniae</i>	6/26 (23.1)	0/25	23.1 (−∞ to 42.3)	
Infection				
HAI	18/107 (16.8)	4/107 (3.7)	13.1 (−∞ to 21.8)	.26
Non-HAI	5/80 (6.3)	3/84 (3.6)	2.7 (−∞ to 10.7)	
Appropriate empirical antibiotic therapy				
Appropriate	18/126 (14.3)	5/127 (3.9)	10.3 (−∞ to 18.0)	.70
Inappropriate	5/61 (8.2)	2/64 (3.1)	5.1 (−∞ to 15.2)	
UT vs non-UT source				
UT	7/102 (6.9)	4/128 (3.1)	3.7 (−∞ to 10.7)	.44
Non-UT	16/85 (18.8)	3/63 (4.8)	14.1 (−∞ to 24.5)	
Immune compromise <sup>c</sup>				
Present	10/51 (19.6)	1/40 (2.5)	17.1 (−∞ to 30.5)	.27
Absent	13/136 (9.6)	6/151 (4.0)	5.6 (−∞ to 12.2)	

Abbreviations: HAI, health care-associated infection; OECD, Organization for Economic Cooperation and Development; UT, urinary tract.

<sup>a</sup> The absolute risk difference was calculated with a 1-sided 97.5% CI using the Miettinen-Nurminen method. The margin for noninferiority was set at 5%. The upper bound of the CI exceeded this threshold in the primary analysis population, thus excluding noninferiority.

<sup>b</sup> Subgroup analyses performed using primary analysis population.

<sup>c</sup> Immune compromise defined by use of cytotoxic chemotherapy, high-dose

corticosteroids (at least 30 mg/d of prednisolone or equivalent), antitumor necrosis factor biological agents (eg, infliximab, etanercept), other immune active monoclonal antibodies (eg, rituximab) or immunosuppressive therapy (eg, tacrolimus, everolimus, methotrexate, cyclosporin, azathioprine, mycophenolate), neutrophil count <500/μL (to convert to ×10<sup>9</sup>/L, multiply by 0.001) on day of bloodstream infection, presence of active solid organ/hematological malignancy, or infection with HIV (with a CD4 count <200/mm<sup>3</sup> or an AIDS-defining condition).

to 0.032 mg/L; EUCAST breakpoint for susceptibility ≤2 mg/L). There was no clear relationship between piperacillin-tazobactam MIC and mortality in patients randomized to receive this drug (eTable 9 in Supplement 2). One *K pneumoniae* strain from Singapore (in a surviving patient randomized to meropenem) demonstrated high-level resistance to piperacillin-tazobactam (MIC ≥256 mg/L) via the presence of *bla*<sub>DHA-1</sub> (AmpC-type β-lactamase). A single *E coli* strain from Turkey (from a surviving patient randomized to meropenem) demonstrated nonsusceptibility to meropenem (MIC, 4 mg/L) via *bla*<sub>OXA-162</sub> (a variant of OXA-48 carbapenemase).


Phenotypic ESBL production was confirmed in 86.0% of isolates (85.0% of *E coli* and 92.5% of *K pneumoniae*). Whole-genome sequencing data were available for 293 (77.3%) of the initial blood culture isolates from patients in the primary analysis population. The dominant *E coli* multilocus ST was ST131 (56.8%), with a small number of multiple other STs represented. For *K pneumoniae*, no ST predominated, although ST25 (16.7%) and ST15 (11.1%) were most common. The K2 capsular serotype, associated with hypervirulence,<sup>33</sup> was the most com-

mon serotype detected in 6 of 36 *K pneumoniae* infections (16.7%); no strains with K1 serotype were identified. ESBL genes were confirmed in 85.3% of isolates, with 10.2% possessing acquired *ampC* genes (predominantly *bla*<sub>CMY-2</sub>); 2.0% carried both ESBL and *ampC*. As previously described,<sup>21</sup> the predominant ESBL genes were *bla*<sub>CTX-M</sub>-type (83.5%), with the most common subtypes being *bla*<sub>CTX-M-15</sub> (54.5%), *bla*<sub>CTX-M-27</sub> (13.0%), and *bla*<sub>CTX-M-14</sub> (11.0%). The presence of narrow-spectrum oxacillinases (such as *bla*<sub>OXA-1</sub> and variants) was also common (seen in 67.6% of all strains), and may compromise β-lactamase inhibition by tazobactam.<sup>34,35</sup>

## Discussion

In patients with *E coli* or *K pneumoniae* bloodstream infection and ceftriaxone resistance, noninferiority of piperacillin-tazobactam for the primary outcome of 30-day mortality could not be demonstrated when compared with meropenem. The overall mortality in this study (7.9%) was lower

Figure 2. Secondary Outcomes



than expected, likely reflecting barriers to recruiting patients into clinical trials with severe infections, as well as the exclusion of individuals who were deemed unlikely to survive beyond 96 hours. Indeed, few patients (10/379, 2.6%) met stratification criteria for high-risk disease (ie, Pitt score >4 and nonurinary focus of infection). However, this would tend to bias this study toward a lower estimate of the mortality risk. The risk of mortality was lower in patients with urinary source of infection, although noninferiority was not demonstrated in the subgroup analysis (accepting that the study was not powered accordingly).

A recent trial of meropenem-vaborbactam vs piperacillin-tazobactam for complicated urinary tract source found superiority of meropenem-vaborbactam over piperacillin-tazobactam for a composite end point of clinical cure or improvement and microbial eradication, even when few carbapenemase-producing strains (the target of the vaborbactam inhibitor component) were present.<sup>36</sup> Whether piperacillin-tazobactam remains effective for urinary infections caused by ESBL producers in patients without BSI or low mortality risk remains uncertain. Efforts to define alternatives to carbapenems remain a priority. Whether newer BLBLI agents (such as ceftolozane-tazobactam or ceftazidime-avibactam) are useful options in this clinical context remains unknown and conclusions on the efficacy of new BLBLIs for these infections should not be drawn from the results of this trial before evaluation within randomized studies.

### Limitations

This study has several limitations. First, the inherent delays in the processing of blood cultures and susceptibility testing means that empirical therapy was not under control of the study team. Many patients (50/191, 26.2%) who were randomized to meropenem received a BLBLI empirically and, con-

versely, 13.8% (26/188) of those randomized to piperacillin-tazobactam received a carbapenem empirically (eTable 3 in Supplement 2). As empirical therapy may have a major influence on outcome, the fact that some “contamination” of drug exposure between the 2 groups exists may complicate inferences. However, this would tend to bias toward noninferiority. This pragmatic study was purposefully designed not to mimic registration drug trials, but to reflect clinical practice where prescribers are faced with a decision point when ceftriaxone nonsusceptibility is known. Second, step-down therapy (which was allowed on day 5 after randomization) with a carbapenem (eg, once-daily ertapenem) occurred in 20.1% (76/379) of all patients, even if randomized to piperacillin-tazobactam (eTable 3 in Supplement 2).

Third, whether adequate source control was achieved in patients with a complex source of BSI is not known and could have influenced mortality if imbalances were present. Fourth, although patients were recruited from diverse geographical and economic regions, only 2 patients were enrolled from North America (Canada), so it is possible that these results are not generalizable to the United States. However, *E coli* strains causing BSI in this study are consistent with the STs and their associated ESBL genes previously described as prevalent in the United States.<sup>37</sup> Piperacillin-tazobactam may be dosed differently in some US hospitals than in this trial (eg, 3.375 g every 6 hours vs 4.5 g of 6 hours),<sup>14</sup> but the lower dosing regimen has been associated with a low probability of achieving optimal drug exposure in ESBL producers.<sup>38</sup> Extended or continuous infusions of piperacillin-tazobactam may optimize drug exposure but the clinical efficacy of this approach remains uncertain.<sup>39</sup>

Fifth, given that the primary treating clinician had to agree to enrollment, this may have introduced spectrum (or case-mix) bias. However, this was a reason for exclusion



in only 123 of 1255 excluded patients (9.8%). Sixth, for missing data variables used to determine clinical and microbiological resolution, imputation by carrying forward the last observation was used, which could bias secondary end point measures. However, a post hoc sensitivity analysis using multiple imputation had no significant effect on these outcomes. Seventh, as an unblinded study, investigators were aware of the treatment allocation and this may have prompted the early cessation of piperacillin-tazobactam if the clinician perceived clinical failure. However, the results were comparable in both the primary analysis and PP populations, suggesting this did not substantially alter the final

results. Furthermore, the primary outcome measure was objective (mortality), mitigating any inherent bias that may be introduced by an open-label study.

## Conclusions

Among patients with *E coli* or *K pneumoniae* bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in noninferior 30-day mortality. These findings do not support use of piperacillin-tazobactam in this setting.

### ARTICLE INFORMATION

**Accepted for Publication:** July 27, 2018.

**Author Affiliations:** University of Queensland, UQ Centre for Clinical Research, Brisbane, Queensland, Australia (Harris, Lorenc, Harris-Brown, Paterson); Department of Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia (Harris); Infection Management Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia (Harris, Looke); Department of Infectious Diseases, National University Hospital, Singapore (Tambyah, Mo); Yong Loo Lin School of Medicine, National University of Singapore, Singapore (Lye, Lee); Department of Infectious Diseases, Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore (Lye, Lee); Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (Lye, Lee); Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Istanbul Medipol University, Istanbul, Turkey (Yilmaz); King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Alenazi, Arabi); Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Italy (Falcone); Infectious Diseases Clinic, Department of Medicine University of Udine and Santa Maria Misericordia Hospital, Udine, Italy (Bassetti, Righi); Monash University, Centre for Inflammatory Diseases, Melbourne, Victoria, Australia (Rogers); Monash Infectious Diseases, Monash Health, Melbourne, Victoria, Australia (Rogers); Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon (Kanj); Department of Medicine and Infectious Diseases, North Shore Hospital, Auckland, New Zealand (Bhally); Marie Bashir Institute for Infectious Disease and Biosecurity, University of Sydney, Sydney, New South Wales, Australia (Iredell); Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, New South Wales, Australia (Iredell); Division of Infectious Diseases & HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa (Mendelson, Boyles); University of Queensland, Brisbane, Queensland, Australia (Looke, Griffin); School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia (Miyakis); Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia (Miyakis); Department of Infectious Diseases, Wollongong Hospital, Wollongong, New South Wales, Australia (Miyakis);

Department of Infectious Diseases, Middlemore Hospital, Auckland, New Zealand (Walls); King Fahad Specialist Hospital, Dammam, Saudi Arabia (Al Khamis, Zikri); Department of Infectious Diseases, St Vincent's Hospital, Melbourne, Victoria, Australia (Crowe); Department of Microbiology, St Vincent's Hospital, Melbourne, Victoria, Australia (Crowe); School of Pathology and Laboratory Medicine, The University of Western Australia, Crawley, Australia (Ingram); Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Australia (Ingram); Department of Microbiology, PathWest Laboratory Medicine, Perth, Western Australia (Ingram); Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada (Daneman); Department of Medicine and Infectious Diseases, Mater Hospital and Mater Medical Research Institute, Brisbane, Queensland, Australia (Griffin); QIMR Berghofer, Brisbane, Queensland, Australia (Griffin); Department of Infectious Diseases, Barwon Health and Deakin University, Geelong, Victoria, Australia (Athan); School of Public Health, University of Queensland, Brisbane, Queensland, Australia (Baker); Australian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, The University of Queensland, Queensland, Australia (Roberts, Beatson); Infection & Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Australia (Peleg); Department of Microbiology, Monash University, Clayton, Australia (Peleg); Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia (Peleg); Department of Infectious Diseases, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia (Paterson).

**Author Contributions:** Drs Harris and Paterson had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors have approved the final version of the manuscript. **Concept and design:** Harris, Rogers, Iredell, Miyakis, Ingram, Athan, Lorenc, Peleg, Paterson. **Acquisition, analysis, or interpretation of data:** Harris, Tambyah, Lye, Mo, Lee, Yilmaz, Alenazi, Arabi, Falcone, Bassetti, Righi, Rogers, Kanj, Bhally, Iredell, Mendelson, Boyles, Looke, Miyakis, Walls, Al Khamis, Zikri, Crowe, Ingram, Daneman, Griffin, Athan, Lorenc, Baker, Roberts, Beatson, Peleg, Harris-Brown, Paterson. **Drafting of the manuscript:** Harris, Lorenc, Roberts, Harris-Brown, Paterson. **Critical revision of the manuscript for important intellectual content:** Harris, Tambyah, Lye, Mo, Lee, Yilmaz, Alenazi, Arabi, Falcone, Bassetti, Righi,

Rogers, Kanj, Bhally, Iredell, Mendelson, Boyles, Looke, Miyakis, Walls, Al Khamis, Zikri, Crowe, Ingram, Daneman, Griffin, Athan, Baker, Beatson, Peleg, Harris-Brown, Paterson.

**Statistical analysis:** Harris, Baker.

**Obtained funding:** Harris, Mo, Ingram, Harris-Brown, Paterson.

**Administrative, technical, or material support:**

Harris, Tambyah, Lye, Mo, Yilmaz, Arabi, Righi, Rogers, Iredell, Boyles, Walls, Crowe, Daneman, Lorenc, Harris-Brown, Paterson.

**Supervision:** Harris, Lye, Alenazi, Arabi, Kanj, Bhally, Miyakis, Walls, Al Khamis, Zikri, Athan, Beatson, Peleg, Harris-Brown, Paterson.

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Harris reported receiving grants from the Australian Society for Antimicrobials; the International Society for Chemotherapy; the National University Hospital Singapore; the Study, Education, and Research Committee of Pathology; and the Royal College of Pathologists of Australasia Foundation. Dr Harris also reported receiving support to speak at an educational event sponsored by Pfizer. Dr Tambyah reported receiving grants from the National University Health System, GlaxoSmithKline, Janssen, Shionogi, Sanofi-Pasteur, Visterra, Baxter, ADAMAS, Merlion Pharmaceuticals, Fabentech, and Inviragen. He has also received honoraria from Novartis and AstraZeneca. Dr Falcone reported receiving personal fees from MSD, Angelini, and Astellas and grants from Gilead. Dr Bassetti reported receiving grants and/or personal fees from Pfizer, MSD, Astellas, Menarini, Roche, Tetrphase, Achaogen, Angelini, AstraZeneca, Bayer, Basilea, Cidara, Gilead, MSD, Paratek, Pfizer, The Medicines Company, and Vifor. Dr Rogers reported receiving grants and personal fees from MSD Australia for attending advisory boards and research and personal fees from Mayne Pharma for consulting. Dr Kanj reported receiving honoraria for speaking and serving on advisory boards for Pfizer, Merck, Bayer, Gilead, Hikma, and Aventis. Ms Lorenc reported receiving grants from the Australian Society for Antimicrobials, the International Society for Chemotherapy, and the National University Hospital Singapore. Dr Beatson reported receiving support for speaking at an educational event sponsored by Pfizer. Dr Peleg reported receiving grants from MSD. Dr Paterson reported receiving grants and/or personal fees from Merck, Pfizer, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, and Cubist. No other disclosures were reported.

**Funding/Support:** The study was sponsored by the University of Queensland. This study was funded by grants from the Australian Society for Antimicrobials (ASA), International Society for Chemotherapy (ISC), National University Hospital Singapore Clinician Researcher Grant NUHSRO/2014/121/CRG/07. Whole-genome sequencing was funded by grants from the Australian Infectious Disease Centre and Australian Genome Research Facility; the Royal College of Pathologists of Australasia (RCPA) Foundation; and the Study, Education, and Research Committee (SERC) of Pathology Queensland. Dr Beatson was supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship during the course of the trial. Dr Harris was supported by an Australian Postgraduate Award from the University of Queensland. Dr Peleg was supported by a NHMRC Career Development and Practitioner Fellowship during the course of the trial. Dr Paterson was supported by a NHMRC Practitioner Fellowship during the course of the trial.

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Group Information:** The MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) members include the following: **Royal Brisbane & Women's Hospital:** John McNamara and Rachel Sieler. **The Alfred Hospital, Melbourne:** Jill Garlick, Jess Costa, Janine Roney, and Nigel Pratt. **American University of Beirut Medical Center, Lebanon:** Houssam Tabaja, Joumana Kmeid, Ralph Tayyar, and Saeed El Zein. **Dandong Hospital, Australia:** Stephanie Jones. **Geelong Hospital, Australia:** Raquel Cowan, Alex Tai, Belinda Lin, Babak Rad, Eleanor MacMorran, and James Pollard. **Istanbul Medipol Mega Hospital Complex, Turkey:** Rumeysa Dinleyici, Ayse Istanbulu, Bahadir Ceylan, and Ali Mert. **King Fahad Specialist Hospital, Dammam, Saudi Arabia:** Mai Hashhoush and Taleb Dalwi. **Monash Medical Centre, Australia:** Tony Korman, Rula Azzam, Michael Birrell, Carly Hughes, Sadid Khan, Jillian Lau, Layyang Lee, Karen Lim, Yi Dani Lin, David Lister, David New, Nastaran Rafiei, James Stewart, Alex Tai, Mohamad Ali Trad, and Victor Aye Yeung. **Middlemore Hospital, Auckland, New Zealand:** Stephen McBride, David Holland, Christopher Hopkins, Christopher Luey, Susan Taylor, and Susan Morpeth. **Mater Hospital, Brisbane, Australia:** Melissa Finney and Megan Martin. **North Shore Hospital, Auckland, New Zealand:** Umit Holland. **National University Hospital, Singapore:** Jaminah Ali and Roland Jureen. **Princess Alexandria Hospital, Brisbane, Australia:** Neil Underwood, Andrew Henderson, and Naomi Runnegar. **Peter McCallum Cancer Centre, Melbourne, Australia:** Monica Slavin. **Royal Perth Hospital and Fiona Stanley Hospital:** Owen Robinson. **Sunnybrook Hospital, Toronto, Canada:** Asgar Rishu. **Wollongong Hospital, Australia:** Samia Shawkat, Janaye Fish, Kwee Chin Liew, and Peter Newton. **Santa Maria Misericordia Hospital, Udine, Italy:** Maria Merelli, Alessia Carnelutti, Silvia Ussai, and Davide Pecori. **Tan Tock Seng Hospital, Singapore:** Ezlyn Izharuddin, Barnaby Young, and Ying Ding. **Westmead**

**Hospital, Sydney, Australia:** Ristila Ram, June Kelly, and Neela Joshi. **Charlotte Maxeke Johannesburg Academic Hospital, South Africa:** Guy Richards, Oliver Smith, and Ahmad Alli. **Groote Schuur Hospital, Cape Town, South Africa:** Inge Vermeulen, Brenda Wright, Chedwin Grey, Annemien Stewart, Denasha Reddy, and Sean Wasserman. **King Abdulaziz Medical City, Riyadh, Saudi Arabia:** Hanie Richi, Khizra Sultana, Nouf Alanazi, and Eman Bin Awad. **Ospedale Luigi Sacco, Milan, Italy:** Fabio Franzetti. **Pretoria Academic Hospital, South Africa:** Anton Stolz, Elsabe De Kock, Tebogo Magongoa, Marizane Dutoit. **"Sapienza" University, Rome, Italy:** Alessandro Russo. **San Remo Hospital:** Chiara Dentone. **Townsville Hospital, Australia:** Damon Eisen, Liz Heyer.

**Additional Contributions:** We thank the data and safety monitoring board for its assistance with the study: Jesus Rodriguez-Baño (Infectious Diseases Division at Hospital Universitario Virgen Macarena, Seville, Spain) and Yohei Doi (Division of Infectious Diseases University of Pittsburgh, Pittsburgh, Pennsylvania), with independent statistical advice from Aaron Dane. Simon Forsyth, PhD (University of Queensland), helped manage the REDCap database. We also thank Henry Chambers MD, PhD (University of California, San Francisco), and Scott Evans, PhD (Harvard University), for their thoughtful review of the manuscript. Amy Jennison, PhD, and Rikki Graham, PhD (Forensic and Scientific Services Laboratory, Queensland), and the Australian Genome Research Facility helped facilitate bacterial whole-genome sequencing. Nouri Ben-Zakour, PhD (University of Sydney), and Mark Schembri, PhD (University of Queensland), also supported the genomic data analysis. Andrew Henderson, MBBS (University of Queensland), Ernest Tan (University of Queensland), and Kyra Cottrell, BAppSc (University of Queensland), assisted with phenotypic testing of the bacterial strains. Mark Chatfield, MSc (University of Queensland), helped attend to reviewers' statistical comments. None of these individuals received compensation for their role in the study. The protocol was developed and endorsed by the ASID-CRN, with input from Jeffrey Lipman, MBBS (University of Queensland), Jason Roberts, PhD (University of Queensland), Andrew Stewardson, MBBS, PhD (Monash University), Sanjoy Paul, PhD (University of Melbourne), and Emma McBryde, MBBS, PhD (James Cook University). They did not receive compensation. We thank the site investigators, collaborators, and research assistants for their help with the study, as well as the participating microbiology laboratories for their assistance with storing and shipping organisms.

## REFERENCES

- Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis*. 2008;8(3):159-166. doi:10.1016/S1473-3099(08)70041-0
- Centers for Disease Control and Prevention. *Antibiotic Resistance Threats in the United States*. Washington, DC: US Department of Health and Human Services; 2013.
- Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev*. 2005;18(4):657-686. doi:10.1128/CMR.18.4.657-686.2005

- Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* infection in the United States. *Clin Infect Dis*. 2013;56(5):641-648. doi:10.1093/cid/cis942
- Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. *N Engl J Med*. 2010;362(19):1804-1813. doi:10.1056/NEJMr0904124
- McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. *Antimicrob Agents Chemother*. 2013;57(10):5131-5133. doi:10.1128/AAC.00607-13
- Chang H-J, Hsu P-C, Yang C-C, et al. Risk factors and outcomes of carbapenem-nonsusceptible *Escherichia coli* bacteremia: a matched case-control study. *J Microbiol Immunol Infect*. 2011;44(2):125-130. doi:10.1016/j.jmii.2010.06.001
- Harris PN, Tambyah PA, Paterson DL.  $\beta$ -lactam and  $\beta$ -lactamase inhibitor combinations in the treatment of extended-spectrum  $\beta$ -lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? *Lancet Infect Dis*. 2015;15(4):475-485. doi:10.1016/S1473-3099(14)70950-8
- Tamma PD, Rodriguez-Bano J. The use of noncarbapenem  $\beta$ -lactams for the treatment of extended-spectrum  $\beta$ -lactamase infections. *Clin Infect Dis*. 2017;64(7):972-980. doi:10.1093/cid/cix034
- Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á. Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group.  $\beta$ -Lactam/ $\beta$ -lactamase inhibitor combinations for the treatment of bacteremia due to extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*: a post hoc analysis of prospective cohorts. *Clin Infect Dis*. 2012;54(2):167-174. doi:10.1093/cid/cir790
- Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae. *Antimicrob Agents Chemother*. 2016;60(7):4159-4169. doi:10.1128/AAC.00365-16
- Ng TM, Khong WX, Harris PN, et al. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. *PLoS One*. 2016;11(4):e0153696. doi:10.1371/journal.pone.0153696
- Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum  $\beta$ -lactamases: a systematic review and meta-analysis. *J Antimicrob Chemother*. 2012;67(12):2793-2803. doi:10.1093/jac/dks301
- Tamma PD, Han JH, Rock C, et al. Antibacterial Resistance Leadership Group. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum  $\beta$ -lactamase bacteremia. *Clin Infect Dis*. 2015;60(9):1319-1325.
- Harris PN, Peleg AY, Iredell J, et al. Meropenem versus piperacillin-tazobactam for definitive

- treatment of bloodstream infections due to ceftriaxone non-susceptible *Escherichia coli* and *Klebsiella* spp (the MERINO trial): study protocol for a randomised controlled trial. *Trials*. 2015;16(1):24. doi:10.1186/s13063-014-0541-9
16. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ*. 2015; 350:h2147.
17. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. *JAMA*. 2012;308(24):2594-2604. doi:10.1001/jama.2012.87802
18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
19. European Committee on Antimicrobial Susceptibility Testing. *Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 7.1*. Basel, Switzerland: EUCAST; 2017.
20. European Committee on Antimicrobial Susceptibility Testing. *EUCAST Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance, Version 2.0*. Basel, Switzerland: EUCAST; 2017.
21. Harris PNA, Ben Zakour NL, Roberts LW, et al; MERINO Trial investigators. Whole genome analysis of cephalosporin-resistant *Escherichia coli* from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27 [published online December 14, 2017]. *J Antimicrob Chemother*. doi:10.1093/jac/dkx466
22. Chow S-C, Wang H, Shao J. *Sample Size Calculations in Clinical Research*. 2nd ed. Boca Raton, FL: Chapman Hall; 2007.
23. Miettinen O, Nurminen M. Comparative analysis of two rates. *Stat Med*. 1985;4(2):213-226. doi:10.1002/sim.4780040211
24. Gart JJ, Nam JM. Approximate interval estimation of the difference in binomial parameters: correction for skewness and extension to multiple tables. *Biometrics*. 1990;46(3):637-643. doi:10.2307/2532084
25. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. *Stat Methods Med Res*. 2007;16(3): 219-242. doi:10.1177/0962280206074463
26. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. <https://www.jstatsoft.org/index.php/jss/article/view/v045i03>. Published 2011. Accessed July 16, 2018.
27. R: A language and environment for statistical computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2017.
28. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med*. 1985;13(10): 818-829. doi:10.1097/00003246-198510000-00009
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40 (5):373-383. doi:10.1016/0021-9681(87)90171-8
30. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. *Int J Antimicrob Agents*. 1999;11(1):7-12. doi:10.1016/S0924-8579(98)00060-0
31. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA*. 2016;315(8): 762-774. doi:10.1001/jama.2016.0288
32. Clinical and Laboratory Standards Institute. *Performance standards for antimicrobial susceptibility testing; twenty third informational supplement. CLSI document M100-S24*. Wayne, PA: CLSI; 2014.
33. Lin JC, Koh TH, Lee N, et al. Genotypes and virulence in serotype K2 *Klebsiella pneumoniae* from liver abscess and non-infectious carriers in Hong Kong, Singapore and Taiwan. *Gut Pathog*. 2014;6:21. doi:10.1186/1757-4749-6-21
34. Sugumar M, Kumar KM, Manoharan A, Anbarasu A, Ramaiah S. Detection of OXA-1  $\beta$ -lactamase gene of *Klebsiella pneumoniae* from blood stream infections (BSI) by conventional PCR and in-silico analysis to understand the mechanism of OXA mediated resistance. *PLoS One*. 2014;9(3): e91800. doi:10.1371/journal.pone.0091800
35. Bethel CR, Distler AM, Ruzsyczky MW, et al. Inhibition of OXA-1  $\beta$ -lactamase by penems. *Antimicrob Agents Chemother*. 2008;52(9):3135-3143. doi:10.1128/AAC.01677-07
36. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. *JAMA*. 2018;319(8):788-799. doi:10.1001/jama.2018.0438
37. Johnson JR, Urban C, Weissman SJ, et al; AMERECUS Investigators. Molecular epidemiological analysis of *Escherichia coli* sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum- $\beta$ -lactamase-producing *E. coli* from the United States, 2000 to 2009. *Antimicrob Agents Chemother*. 2012;56(5):2364-2370. doi:10.1128/AAC.05824-11
38. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against *Escherichia coli* and *Klebsiella pneumoniae* strains producing extended-spectrum beta-lactamases: report from the ARREST program. *Antimicrob Agents Chemother*. 2003;47(5):1643-1646. doi:10.1128/AAC.475.1643-1646.2003
39. Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and  $\beta$ -lactam/ $\beta$ -lactamase inhibitors in the treatment of infections caused by extended-spectrum- $\beta$ -lactamase-producing Enterobacteriaceae. *J Antimicrob Chemother*. 2014; 69(4):871-880. doi:10.1093/jac/dkt450